Relmada Therapeutics, Inc.
NCM: RLMDLive Quote
📈 ZcoreAI Score
Our AI model analyzes Relmada Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get RLMD Z-Score →About Relmada Therapeutics, Inc.
Healthcare
Biotechnology
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
📊 Fundamental Analysis
Relmada Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -25.6%, which indicates that capital utilization is currently under pressure.
At a current price of $7.29, RLMD currently trades near the top of its 52-week range (92%) (Range: $0.27 - $7.94).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$764.65M
Trailing P/E
--
Forward P/E
-17.78
Beta (5Y)
--
52W High
$7.94
52W Low
$0.27
Avg Volume
1.64M
Day High
Day Low